Catalog No.: PC-24555Not For Human Use, Lab Use Only.
PLX-4545 (PLX4545) is a potent and selective, orally bioavailable IKZF2 degrader, that depletes IKZF2 and converts suppressive Tregs into effector-like T-cells leading to antitumor immunity.
PLX-4545 (PLX4545) is a potent and selective, orally bioavailable IKZF2 degrader, that depletes IKZF2 and converts suppressive Tregs into effector-like T-cells leading to antitumor immunity.
Oral administration of PLX-4545 resulted in dose dependent depletion of IKZF2 and single agent antitumor activity in vivo.
PLX-4545 treatment preferentially converted tumor Tregs into effector-like T-cells through decreased CD25 expression and increased production of effector cytokines (IL2, IFNγ), resulting in increased infiltration of CD4/8 Teff cells into tumor tissue.
Combination of PLX-4545 with anti-PD1 significantly increased the proliferation of Teff cells and inhibition of tumor growth in vivo.
